A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...

A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of ...

While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.

With immunotherapy increasingly making it out of the lab and into hospitals as a viable way to treat serious conditions like ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

Specifically, the FDA removed the Risk Evaluation and Mitigation Strategy (REMS) program requirements from two BCMA-directed CAR T-cell therapies for multiple myeloma — ciltacabtagene autoleucel ...

A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...

The US Food and Drug Administration (FDA) has announced the elimination of the Risk Evaluation and Mitigation Strategies ...

The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and ...

Researchers have pioneered a novel 3D platform that mimics the human bone marrow and immune environment, enabling more ...

Thermo Fisher Scientific Inc. (NYSE:TMO) ranks among the best CRISPR stocks to buy. On June 24, Thermo Fisher Scientific Inc. (NYSE:TMO) partnered with Xcell Biosciences, an instrumentation firm ...

FDA updates CAR T-cell therapy labels, easing monitoring requirements and expanding access for eligible patients in oncology.